摘要
目的 探讨横纹肌肉瘤 (RMS)中凋亡抑制蛋白c IAP1、c IAP2和survivin表达与临床病理特点的关系。方法 采用免疫组织化学技术 (S P法 )和图像分析技术检测 4 3例横纹肌肉瘤及 15例正常横纹肌组织中c IAP1、c IAP2和survivin表达水平 ,并结合临床病理特征进行分析。结果 c IAP1和c IAP2在RMS中均有表达 ,RMS中c IAP1和c IAP2表达水平高于正常横纹肌组织 (P <0 0 5 )。survivin在 86 % (37/ 4 3)的RMS中表达 ,且表达水平高于正常横纹肌组织 (P <0 0 5 )。c IAP1、c IAP2和survivin在胚胎性横纹肌肉瘤 (ERMS)和腺泡状横纹肌肉瘤 (ARMS)中的表达水平差异无显著性 (P >0 0 5 ) ,但c IAP2和survivin的表达水平在不同分化程度的RMS之间差异有显著性 (P <0 0 5 )。有复发 /转移的RMS与无复发 /转移的RMS相比 ,c IAP1、c IAP2和survivin表达较高 (P <0 0 5 )。结论 c IAPs和survivin在RMS中的表达水平增加 ;c IAP2和survivin的表达与横纹肌肉瘤细胞分化有关。c IAP1、c IAP2和survivin的高表达可能作为横纹肌肉瘤病人预后不良的标志。
Purpose To investigate the expression of the inhibitor of apoptosis proteins c IAP1, c IAP2 and survivin in rhabdomyosarcoma (RMS), and their relationship to clinicopathological features. Methods Immunohistochemical technique (S P) and image analysis were used to assess the expression levels of c IAP1, c IAP2 and survivin in 43 cases of RMS and 15 normal skeletal muscle samples. Results Expression of c IAP1 and c IAP2 was observed in both RMS and normal skeletal muscle, with higher levels in RMS ( P <0 05). Expression of survivin was detected in 86% RMS, with higher levels in RMS than in normal skeletal muscles ( P <0 05). No significant difference was observed for c IAP1, c IAP2 and survivin expression levels between ERMS and ARMS, but significant difference was observed for c IAP2 and survivin expression levels among RMS with different degrees of differentiatation. Expression levels of c IAP1, c IAP2 and survivin in RMS with recurrence or metastasis were higher than that in RMS without recurrence or metastasis. Conclusions Expression levels of c IAPs and survivin are increased in RMS. Expression levels of c IAP2 and survivin are related to the degree of differentiation of RMS, and higher levels of c IAP1, c IAP2 and survivin may indicate unfavourable prognosis for RMS patients.
出处
《临床与实验病理学杂志》
CAS
CSCD
2003年第2期141-144,共4页
Chinese Journal of Clinical and Experimental Pathology
基金
国家杰出青年科学基金 (No 3 0 12 5 0 2 3 )
教育部回国人员启动基金 (No 2 0 0 1-4 98)资助